Organovo Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Esousa Group Holdings LLC and Michael Wachs have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in VivoSim Labs, Inc.
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose Reduced Stake in Organovo Holdings Below 5%
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting their beneficial ownership in Organovo Holdings, Inc. has decreased to 4.99% of the common stock.
Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Organovo Holdings, Inc., totaling 1,700,684 shares.